Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Q2 2026 Earnings Presentation
6 slides from Vitrolife Ab's earnings presentation, 2026
Slide 1: Pre-silent call prior to Q2 2026
Vitrolife AB ( publ) Pre-silent call prior to Q2 2026 Pär Ihrskog, CFO
Slide 2: Key factors to consider in Q2 2026 – Market update
Key factors to consider in Q2 2026 – Market update • EMEA: • European cycle activity at normal levels. • Middle East Crisis: Impacting IVF cycles significantly in the region. We do not see distributors restocking at this time. • China: IVF cycles are declining year over year; this trend is expected
Slide 3: Key factors to consider in Q2 2026 – Vitrolife Group update
Key factors to consider in Q2 2026 – Vitrolife Group update • Restructuring programto rationalise the portfolio and exit low profit markets ison track. • We are proactively exiting low price/low margin markets in all regions. • As communicated in December thetopline impact of these exits of -3%. 2 •
Slide 4: Key factors to consider in Q2 2026 – Organisational update
Key factors to consider in Q2 2026 – Organisational update • CEO transition: Well- managed and orderly transition underway. Recruitment has commencedand Bronwyn Brophy will remain in place for up to 12 months, ensuring strategic continuity and operational stability while the succession process progr
Slide 5: New Chief Operating Officer
New Chief Operating Officer • Olivier Desmarets appointed as new Chief Operations Officer (COO) following Ermanno Sironi's retirement. • Responsible for leading the company's global operations, including Manufacturing, Labs, Supply chain & Procurement, Qualityand IT. • More than 20 years of internat
Slide 6: Disclaimer
Disclaimer This presentation may contain estimates and forward - looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, th